NextFin News - Roche said its divarasib pill beat approved KRAS G12C drugs in a phase III lung-cancer trial, giving the Swiss drugmaker a potentially important edge in a small but commercially meaningful oncology niche. In a July 2 announcement, Roche said the Krascendo 1 study met its primary and key secondary endpoints, with divarasib showing clinically meaningful and statistically significant improvements in progression-free survival and overall survival versus sotorasib or adagrasib.
The Trial Put Roche In Direct Competition With The Current Standard
The result matters because Krascendo 1 was a direct head-to-head study in previously treated patients with KRAS G12C-mutant non-small cell lung cancer. Roche said the trial enrolled 338 adults and randomized them to once-daily divarasib or to approved first-generation KRAS G12C inhibitors, either sotorasib once daily or adagrasib twice daily.
That design makes the readout more consequential than an early-stage efficacy signal. Instead of comparing divarasib with placebo or with a loosely matched control group, Roche tested the drug against the therapies doctors already use in this biomarker-defined market. The company also said Krascendo 1 is the only global head-to-head study of a KRAS G12C inhibitor against first-generation drugs.
The primary endpoint was blinded independent central review-assessed progression-free survival. Secondary measures included overall survival, confirmed objective response and duration of response. Roche did not publish the exact size of the benefit in the release, but it did say the study met both its primary and key secondary endpoint, which indicates the company believes the survival result was strong enough to carry regulatory and commercial weight.
“The superior survival demonstrated in this global head-to-head comparison of KRAS G12C inhibitors confirms the potential of divarasib to improve clinical outcomes for people with KRAS G12C non-small cell lung cancer,” said Levi Garraway, Roche’s chief medical officer and head of global product development.
That statement matters because Roche is not describing divarasib as a marginally active drug. It is arguing for a class-leading profile in a setting where small differences can influence treatment choice, especially after patients have already been exposed to prior therapy.
A Safety Profile That Did Not Show New Problems
Roche said divarasib’s safety profile remained consistent with previous data, with no new findings and the most common treatment-related events manageable and reversible. In KRAS-targeted lung cancer, that is a crucial part of the story. A drug that wins on efficacy but creates a new tolerability burden often struggles to convert clinical interest into routine use.
The company did not provide the detailed adverse-event table in the announcement, so the exact tolerability advantage, if any, remains to be seen. Even so, the absence of new safety issues is meaningful because it reduces the risk that the survival win came with a trade-off that could limit adoption.
Roche also said divarasib has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and Orphan Drug Designation in 2026 for KRAS G12C non-small cell lung cancer. Those designations do not guarantee approval, but they show regulators have already treated the program as a priority.
The practical question now is whether the detailed data presentation confirms the kind of benefit profile Roche appears to be signaling. If the numbers hold up in the full dataset, divarasib could become one of Roche’s most important oncology assets in development.
Why The Readout Matters For Roche’s Broader Pipeline
Divarasib has now moved from a promising pipeline name to a late-stage asset with a positive phase III result in a setting where differentiation is hard to prove. That matters for Roche because the company has been working to refresh its oncology portfolio as older products mature and competition intensifies across targeted therapies.
KRAS G12C is a particularly relevant battleground. It is a biomarker-defined market with limited direct competitors, which means a drug that can prove superiority in a head-to-head trial has a real shot at changing prescribing behavior. Roche is therefore not just chasing approval; it is trying to establish divarasib as a better option than the first-generation drugs that already define the category.
Roche said data from Krascendo 1 will be presented at an upcoming medical meeting and submitted to health authorities as soon as possible. That means investors and clinicians still need the full efficacy and subgroup detail before drawing firm conclusions about the size and durability of the opportunity.
Even so, the strategic message is already clear. Roche has a phase III win in a targeted lung-cancer space that is small enough for precision medicine to matter and large enough to justify the fight. The next step is whether the company can turn that trial result into a regulatory filing and, eventually, into market share.
The broad implication is not that Roche has solved lung cancer. It is that the company has found a potentially stronger answer in one of the more valuable mutation-specific corners of the disease. In biotech, that kind of result can redraw the competitive map long before the drug reaches the market.
Explore more exclusive insights at nextfin.ai.
